Luye Pharma Group (HKG:2186) booked 618.7 million yuan in attributable profit for 2025, rising 31% from 471.9 million yuan in 2024, according to a Hong Kong bourse filing Tuesday.
Earnings per share were 0.1250 yuan, compared with 0.1254 yuan in the prior year.
Revenue rose 4.1% year on year to 6.31 billion yuan, figures showed.
The company did not declare a final dividend for the year.
Shares of the company were up nearly 3% in recent trade.